[1] |
BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
|
[2] |
CHEN Z,FILLMORE C M,HAMMERMAN P S,et al. Non-small-cell lung cancers:a heterogeneous set of diseases[J]. Nat Rev Cancer,2014,14(8):535-546.
|
[3] |
YU H A,ARCILA M E,REKHTMAN N,et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers[J]. Clin Cancer Res,2013,19(8):2240-2247.
|
[4] |
LEE C K,NOVELLO S,RYDÉN A,et al. Patient-reported symptoms and impact of treatment with osimertinib versus chemotherapy in advanced non-small-cell lung cancer:the AURA3 trial[J]. J Clin Oncol,2018,36(18):1853-1860.
|
[5] |
OXNARD G R,THRESS K S,ALDEN R S,et al. Association between plasma genotyping and outcomes of treatment with osimertinib(AZD9291) in advanced non-small-cell lung cancer[J]. J Clin Oncol,2016,34(28):3375-3382.
|
[6] |
RODDA A E,PARKER B J,SPENCER A,et al. Extending circulating tumor DNA analysis to ultralow abundance mutations:techniques and challenges[J]. ACS Sens,2018,3(3):540-560.
|
[7] |
WU Y L,SAIJO N,THONGPRASERT S,et al. Efficacy according to blind independent central review:post-hoc analyses from the phase Ⅲ,randomized,multicenter,IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC[J]. Lung Cancer,2017,104:119-125.
|
[8] |
LIM S M,SYN N L,CHO B C,et al. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer:mechanisms and therapeutic strategies[J]. Cancer Treat Rev,2018,65:1-10.
|
[9] |
WU S G,SHIH J Y. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer[J]. Mol Cancer,2018,17(1):38.
|
[10] |
SORENSEN B S,WU L,WEI W,et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib[J]. Cancer,2014,120(24):3896-3901.
|
[11] |
WANG L,GUO Q,YU W,et al. Quantification of plasma EGFR mutations in patients with lung cancers:comparison of the performance of ARMS-Plus and droplet digital PCR[J]. Lung Cancer,2017,114:31-37.
|
[12] |
SACHER A G,PAWELETZ C,DAHLBERG S E,et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer[J]. JAMA Oncol,2016,2(8):1014-1022.
|
[13] |
PAWELETZ C P,SACHER A G,RAYMOND C K,et al. Bias-corrected targeted next-generation sequencing for rapid,multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients[J]. Clin Cancer Res,2016,22(4):915-922.
|
[14] |
ZHANG R,CHEN B,TONG X,et al. Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA[J]. Cancer Manag Res,2018,10:1209-1218.
|
[15] |
THRESS K S,BRANT R,CARR T H,et al. EGFR mutation detection in ctDNA from NSCLC patient plasma:a cross-platform comparison of leading technologies to support the clinical development of AZD9291[J]. Lung Cancer,2015,90(3):509-515.
|
[16] |
FENG Q,GAI F,SANG Y,et al. A comparison of QuantStudioTM 3D Digital PCR and ARMS-PCR for measuring plasma EGFR T790M mutations of NSCLC patients[J]. Cancer Manag Res,2018,10:115-121.
|